Gilead agreed to acquire Arcellx for $7.8 billion to secure full control of anito‑cel, a BCMA‑directed CAR‑T therapy nearing regulatory review. The transaction, announced by Gilead and Arcellx, consolidates development and commercial rights ahead of an FDA decision expected under the PDUFA timeline. Anito‑cel is positioned as a potential fourth‑line multiple myeloma therapy and a direct competitor to J&J/Legend’s Carvykti. The deal replaces prior profit‑sharing and milestone structures between Kite (a Gilead company) and Arcellx, and includes a contingent value right tied to future sales. Gilead cited positive pivotal data and the strategic fit with its cell therapy portfolio in public statements. Investors reacted sharply: Arcellx stock spiked while Gilead shares ticked lower on the news. Analysts and clinical investigators noted the acquisition accelerates Gilead’s bid to regain momentum in cell therapies by owning an asset with an established clinical dataset. The companies said they expect the deal to close in 2Q 2026 and will pursue commercialization planning contingent on regulatory outcomes.